Maneo 150 Mg Prolonged-Release Tablets
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Maneo 150 mg Prolonged-release tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Prolonged-release tablet contains 150 mg of tramadol hydrochloride
Excipient with known effects':
Each tablet contains 0.3 mg of lactose monohydrate
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Prolonged-release tablet.
Maneo 150 mg Prolonged-release tablets: Pale orange coloured, oval shaped, biconvex, film coated tablet, debossed with “M” on one side and “TM2” on other side
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Treatment of moderate to severe pain
4.2 Posology and method of administration
The dose should be adjusted to the intensity of the pain and the sensitivity of the individual patient. The lowest effective dose for analgesia should generally be selected. Unless otherwise prescribed, Maneo should be administered as follows:
Adults and adolescents above the age of 12 years:
The usual initial dose is 50 to 100 mg tramadol hydrochloride twice daily, morning and evening. If pain relief is insufficient, the dose may be titrated upwards to 150 mg or 200 mg tramadol hydrochloride twice daily.
Dependent upon the needs of the patient, subsequent doses may be administered earlier than 12 hours, but must not be administered earlier than 8 hours after the previous dose. Under no circumstances should more than two doses be taken in any one 24 hour period.
For doses not practicable with this strength, other strengths of this medicinal product are available.
The lowest analgesically effective dose should generally be selected. Daily doses of 400 mg active substance should not be exceeded, except in special clinical circumstances.
Maneo tablets should under no circumstances be administered for longer than absolutely necessary. If long-term pain treatment with Maneo tablets is necessary in view of the nature and severity of the illness, then careful and regular monitoring should be carried out (if necessary with breaks in treatment) to establish whether and to what extent further treatment is necessary.
Paediatric population
Maneo tablets are not suitable for children below the age of 12 years.
Geriatric patients
A dose adjustment is not usually necessary in elderly patients (up to 75 years) without clinically manifest hepatic or renal insufficiency. In elderly patients (over 75 years) elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements.
Renal Insufficiency/Dialysis and Hepatic Impairment
In patients with renal and/or hepatic insufficiency the elimination of tramadol is delayed. In these patients prolongation of the dosage interval should be carefully considered according to the patients requirements. In cases of severe renal and/or severe hepatic insufficiency Maneo tablets are not recommended.
Method of administration
The tablets are to be taken whole, not divided or chewed, with sufficient liquid, independent of meals.
4.3 Contraindications
Maneo tablets are contraindicated:
in hypersensitivity to tramadol hydrochloride or any of the excipients (see section 6.1),
in acute intoxication with alcohol, hypnotics, analgesics, opioids, or psychotropic medicinal products,
in patients who are receiving MAOIs (monoamine oxidase inhibitors) or who have taken them within the last 14 days (see section 4.5), in patients with epilepsy not adequately controlled by treatment, for use in narcotic withdrawal treatment
4.4 Special warnings and precautions for use
Maneo tablets may only be used with particular caution in opioid-dependent patients, patients with head injury, shock, a reduced level of consciousness of uncertain origin, disorders of the respiratory centre or function, increased intracranial pressure, patients with moderate to severe impaired liver or kidney function.
In patients sensitive to opiates the product should only be used with caution.
Maneo tablets should not be used in combination with alcohol.
Care should be taken when treating patients with respiratory depression, or if concomitant CNS depressant drugs are being administered (see section 4.5), or if the recommended dosage is significantly exceeded (see section 4.9) as the possibility of respiratory depression cannot be excluded in these situations.
Convulsions have been reported in patients receiving tramadol hydrochloride at the recommended dose levels. The risk may be increased when doses of tramadol hydrochloride exceed the recommended upper daily dose limit (400 mg). In addition, tramadol hydrochloride may increase the seizure risk in patients taking other medicinal products that lowers the seizure threshold (see section 4.5). Patients with epilepsy or those susceptible to seizures should be only treated with tramadol hydrochloride if there are compelling circumstances.
Tramadol hydrochloride has a low dependence potential. On long-term use tolerance, psychic and physical dependence may develop. In patients with a tendency to drug abuse or dependence, treatment with Maneo tablets should only be carried out for short periods under strict medical supervision.
Tramadol hydrochloride is not suitable as a substitute in opioid-dependent patients. Although it is an opioid agonist, tramadol cannot suppress morphine withdrawal symptoms.
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product
4.5 Interaction with other medicinal products and other forms of interaction
Maneo tablets should not be combined with MAOIs (see section 4.3).
In patients treated with MAOIs in the 14 days prior to the use of the opioid pethidine, life-threatening interactions on the central nervous system, respiratory and cardiovascular function have been observed. The same interactions with MAOIs cannot be ruled out during treatment with Maneo tablets.
Concomitant administration of Maneo tablets with other centrally depressant medicinal products including alcohol may potentiate the CNS effects (see section 4.8).
The results of pharmacokinetic studies have so far shown that on the concomitant or previous administration of cimetidine (enzyme inhibitor) clinically relevant interactions are unlikely to occur. Simultaneous or previous administration of carbamazepine (enzyme inducer) may reduce the analgesic effect and shorten the duration of action.
The combination with mixed agonist/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) and tramadol hydrochloride is not advisable, because the analgesic effect of a pure agonist may be theoretically reduced in such circumstances.
Tramadol can induce convulsions and increase the potential for selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic anti-depressants, anti-psychotics and other seizure threshold lowering medicinal products (such as bupropion, mirtazapine, tetrahydrocannabinol) to cause convulsions.
Concomitant therapeutic use of tramadol and serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors (see section 4.3), tricyclic antidepressants and mirtazapine may cause serotonin toxicity. Serotonin syndrome is likely when one of the following is observed:
Spontaneous clonus
Inducible or ocular clonus with agitation or diaphoresis Tremor and hyperreflexia
Hypertonia and body temperature > 38 °C and inducible or ocular clonus. Withdrawal of the serotoninergic medicinal products usually brings about a rapid improvement. Treatment depends on the nature and severity of the symptoms.
Caution should be exercised during concomitant treatment with tramadol hydrochloride and coumarin derivatives (e.g. warfarin) due to reports of increased INR with major bleeding and ecchymoses in some patients.
Other active substances known to inhibit CYP3A4, such as ketoconazole and erythromycin, might inhibit the metabolism of tramadol (N-demethylation) probably also the metabolism of the active O-demethylated metabolite. The clinical importance of such an interaction has not been studied (see section 4.8).
In a limited number of studies the pre- or postoperative application of the antiemetic 5-HT3 antagonist ondansetron increased the requirement of tramadol hydrochloride in patients with postoperative pain.
4.6 Fertility, Pregnancy and lactation
Pregnancy
There are no or limited amount of data from the use of tramadol hydrochloride in pregnant women.
Studies in animals have shown reproductive toxicity. Animal studies with tramadol revealed at very high doses effects on organ development, ossification and neonatal mortality. Teratogenic effects were not observed. Tramadol crosses the placenta (see section 5.3).
Maneo tablets are not recommended during pregnancy and in women of childbearing potential not using contraception.
Tramadol hydrochloride - when administered before or during birth - does not affect uterine contractility. In neonates it may induce changes in the respiratory rate which are usually not clinically relevant. Chronic use during pregnancy may lead to neonatal withdrawal symptoms.
Breastfeeding
Tramadol hydrochloride has been identified in breastfed newborns/infants of treated women. During lactation about 0.1% of the maternal dose is secreted into the milk.
There is insufficient information on the effects of tramadol hydrochloride in newborns/infants. After a single administration of tramadol it is not usually necessary to interrupt breast-feeding.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Maneo tablets therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman
4.7 Effects on ability to drive and use machines
Even when taken according to instructions, Maneo tablets may cause effects such as somnolence and dizziness and therefore may impair the reactions of drivers and machine operators. This applies particularly in conjunction with alcohol and other psychotropic substances.
This medicine can impair cognitive function and can affect a patient’s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine.
• However, you would not be committing an offence (called ‘statutory defence’) if:
o The medicine has been prescribed to treat a medical or dental problem and
o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
o It was not affecting your ability to drive safely
4.8 Undesirable effects
The most commonly reported adverse reactions are nausea and dizziness, both occurring in more than 10 % of patients.
The frequencies used in the table below are according to the following convention:
very common (> 1/10), common (> 1/100 to <1/10), uncommon (> 1/1,000 to <1/100), rare (> 1/10,000 to <1/1000) and very rare (<1/10,000),
not known (cannot be estimated from the available data)
|
System Organ Class |
Frequency |
Adverse drug reactions |
|
Immune system disorders |
Rare |
Anaphylaxis, allergic reactions (e.g. dyspnoea, bronchospasm, wheezing, angioneurotic oedema) |
|
Metabolism and nutrition disorders |
Not known |
Decrease in blood sugar level. |
|
Psychiatric disorders |
Rare |
Hallucinations, confusion, sleep disturbance, anxiety and nightmares. Psychic adverse reactions may occur following administration of Maneo tablets which vary individually in intensity and nature (depending on personality and duration of treatment). These include changes in mood (usually elation, occasionally dysphoria), changes in activity (usually suppression, occasionally increase) and changes in cognitive and sensorial capacity (e.g. decision behaviour, perception disorders). Dependence may occur. Symptoms of withdrawal reactions, similar to those occurring during opiate withdrawal, may occur as follows: agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal symptoms. Other symptoms that have very rarely been seen with tramadol hydrochloride discontinuation include: panic attacks, severe anxiety, hallucinations, paraesthesias, tinnitus and unusual CNS symptoms (i.e. confusion, delusions, depersonalisation, derealisation, paranoia). |
|
Nervous system disorders |
Very common |
Dizziness |
|
Common |
Headache, somnolence |
|
Rare Not known: |
Changes in appetite, paraesthesia, tremor, respiratory depression, epileptiform convulsions, involuntary muscle contractions, abnormal coordination, syncope * Speech disorders | |
|
Eye disorders |
Rare |
Blurred vision |
|
Not known |
Mydriasis | |
|
Cardiovascular |
Uncommon |
Cardiovascular regulation (palpitation, tachycardia, |
|
disorders |
Rare |
postural hypotension or cardiovascular collapse. These adverse reactions may occur especially on intravenous administration and in patients who are physically stressed. Bradycardia, increase in blood pressure |
|
Respiratory, thoracic and mediastinal |
Rare |
Dyspnoea |
|
disorders |
Not known |
Worsening of asthma has been reported, though a causal relationship has not been established. |
|
Gastrointestinal |
Very |
Nausea |
|
disorders |
common | |
|
Common |
Vomiting, constipation, dry mouth | |
|
Uncommon |
Retching; gastrointestinal irritation (a feeling of pressure in the stomach, bloating), diarrhoea | |
|
Hepatobiliary disorders |
Very rare |
Increase liver enzyme values |
|
Skin and subcutaneous tissue disorders |
Common |
Sweating |
|
Uncommon |
Dermal reactions (e.g. pruritus, rash, urticaria) | |
|
Musculoskeletal and connective tissue disorders |
Rare |
Muscle weakness |
|
Renal and urinary |
Rare |
Micturition disorders (difficulty in passing urine, |
|
disorders |
dysuria and urinary retention) | |
|
General Disorders and administration site disorders |
Common |
Fatigue |
* If the recommended doses are considerably exceeded and other centrally depressant
substances are administered concomitantly (see section 4.5), respiratory depression may occur. Epileptiform convulsions occurred mainly after administration of high doses of tramadol hydrochloride or after concomitant treatment with medicinal products which can lower the seizure threshold (see sections 4.4 and 4.5).
4.9 Overdose
Symptoms
In principle, on intoxication with tramadol hydrochloride symptoms similar to those of other centrally acting analgesics (opioids) are to be expected. These include in particular miosis, vomiting, cardiovascular collapse, consciousness disorders up to coma, convulsions and respiratory depression up to respiratory arrest.
Treatment
The general emergency measures apply. Protect the airway, maintain respiration and circulation depending on the symptoms. The antidote for respiratory depression is naloxone. In animal experiments naloxone had no effect on convulsions. In such cases diazepam should be given intravenously. In case of intoxication with oral formulations, gastrointestinal decontamination with activated charcoal or by gastric lavage is only recommended within 2 hours after tramadol hydrochloride intake. Gastrointestinal decontamination at a later time point may be useful in case of intoxication with exceptionally large quantities or prolonged-release formulations.
Tramadol hydrocloride is minimally eliminated from the serum by haemodialysis or haemo-filtration. Therefore treatment of acute intoxication with Maneo tablets with haemodialysis or haemofiltration alone is not suitable for detoxification
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: other opioids; ATC-code N 02 AX 02
Tramadol hydrochloride is a centrally acting opioid analgesic. It is a nonselective pure agonist at p, 5 and k opioid receptors with a higher affinity for the p receptor. Other mechanisms which contribute to its analgesic effect are inhibition of neuronal reuptake of noradrenaline and enhancement of serotonin release.
Tramadol hydrochloride has an antitussive effect. In contrast to morphine, analgesic doses of tramadol over a wide range have no respiratory depressant effect. Also gastrointestinal motility is less affected. Effects on the cardiovascular system tend to be slight. The potency of tramadol is reported to be 1/10 (one tenth) to 1/6 (one sixth) that of morphine
5.2 Pharmacokinetic properties
More than 90% of tramadol hydrochloride is absorbed after oral administration. The mean absolute bioavailability is approximately 70 %, irrespective of the concomitant intake of food. The difference between absorbed and non-metabolised available tramadol hydrochloride is probably due to the low first-pass effect. The first-pass effect after oral administration is a maximum of 30 %.
Tramadol hydrochloride has a high tissue affinity (V d,B= 203 ± 40 l). It has a plasma protein binding of about 20 %.
After administration of tramadol hydrochloride 100 mg prolonged-release tablets the peak plasma concentration Cmax =141 ± 40 ng/ml is reached after
4.9 h. After administration of tramadol hydrochloride 200 mg prolonged-release tablets Cmax 260 ± 62 ng/ml is reached after 4.8 hours.
Tramadol hydrochloride passes the blood-brain and placental barriers. Very small amounts of the substance and its O-desmethyl derivative are found in the breast-milk (0.1 % and 0.02 % respectively of the applied dose).
Elimination half-life t1/2,B is approximately 6 h, irrespective of the mode of administration. In patients above 75 years of age it may be prolonged by a factor of approximately 1.4.
In humans tramadol hydrocloride is mainly metabolised by means of N- and O-demethylation and conjugation of the O-demethylation products with glucuronic acid. Only O-desmethyltramadol is pharmacologically active. There are considerable interindividual quantitative differences between the other metabolites.
So far, eleven metabolites have been found in the urine. Animal experiments have shown that O-desmethyltramadol is more potent than the parent substance by the factor 2 - 4. Its half-life t1/2,B (6 healthy volunteers) is 7.9 h (range 5.4 - 9.6 h) and is approximately that of tramadol hydrochloride.
The inhibition of one or both types of the isoenzymes CYP3A4 and CYP2D6 involved in the biotransformation of tramadol hydrochloride may affect the plasma concentration of tramadol or its active metabolite. Up to now, clinically relevant interactions have not been reported.
Tramadol hydrochloride and its metabolites are almost completely excreted via the kidneys. Cumulative urinary excretion is 90 % of the total radioactivity of the administered dose. In cases of impaired hepatic and renal function the half-life may be slightly prolonged. In patients with cirrhosis of the liver, elimination half-lives of 13.3 ± 4.9 h (tramadol) and 18.5 ± 9.4 h (O-desmethyltramadol), in an extreme case 22.3 h and 36 h respectively, have been determined. In patients with renal insufficiency (creatinine clearance < 5 ml/min) the values were 11 ± 3.2 h and 16.9 ± 3 h, in an extreme case 19.5 h and 43.2 h respectively.
Tramadol hydrochloride has a linear pharmacokinetic profile within the therapeutic dosage range.
The relationship between serum concentrations and the analgesic effect is dose-dependent, but varies considerably in isolated cases. A serum concentration of 100 - 300 ng/ml is usually effective
5.3 Preclinical safety data
On repeated oral and parenteral administration of tramadol hydrochloride for 6 - 26 weeks in rats and dogs and oral administration for 12 months in dogs haematological, clinico-chemical and histological investigations showed no evidence of any substance-related changes. Central nervous manifestations only occurred after high doses considerably above the therapeutic range: restlessness, salivation, convulsions, and reduced weight gain. Rats and dogs tolerated oral doses of 20 mg/kg and 10 mg/kg body weight respectively, and dogs rectal doses of 20 mg/kg body weight without any reactions.
In rats tramadol hydrochloride dosages from 50 mg/kg/day upwards caused toxic effects in dams and raised neonate mortality. In the offspring retardation occurred in the form of ossification disorders and delayed vaginal and eye opening. Male fertility was not affected. After higher doses (from 50 mg/kg/day upwards) females exhibited a reduced pregnancy rate. In rabbits there were toxic effects in dams from 125 mg/kg upwards and skeletal anomalies in the offspring.
In some in-vitro test systems there was evidence of mutagenic effects. In-vivo studies showed no such effects. According to knowledge gained so far, tramadol can be classified as non-mutagenic.
Studies on the tumorigenic potential of tramadol hydrochloride have been carried out in rats and mice.
The study in rats showed no evidence of any substance-related increase in the incidence of tumours. In the study in mice there was an increased incidence of liver cell adenomas in male animals (a dose-dependent, non-significant increase from 15 mg/kg upwards) and an increase in pulmonary tumours in females of all dosage groups (significant, but not dose-dependent)
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Cellulose, microcrystalline Hypromellose Silica, colloidal ahydrous Magnesium stearate
Film-coating 150 mg: Hypromellose (E464) Lactose monohydrate Talc (E553 b)
Macrogol
Propylene glycol (E1520) Titanium dioxide (E171)
Iron oxide red (E172)
Iron oxide brown (E172)
Lake quinoline yellow (E104)
6.2 Incompatibilities
Not applicable
6.3 Shelf life
For Al/OPA/PVC/Al blisters 2 years
For HDPE bottles and Al/PVC/PE/PVDC blisters 3 years
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions
6.5 Nature and contents of container
HDPE Bottles with polypropylene child-resistant closures containing 100 prolonged-release tablets.
HDPE Bottles with polypropylene screw-cap closures containing 500 and 1000 prolonged-release tablets (Dispensing package).
Al/OPA/PVC/Al and Al/PVC/PE/PVDC blisters in cardboard cartons containing 10, 20, 20x1, 28, 30, 50, 56, 60, 60x1, 90 and 100 prolonged-release tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements
7 MARKETING AUTHORISATION HOLDER
Generics [UK] Ltd
Potters Bar, Hertfordshire, EN6 1TL,
United Kingdom
MARKETING AUTHORISATION NUMBER(S)
PL 04569/1407
9
10
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
06/09/2012
DATE OF REVISION OF THE TEXT
27/05/2015